{
    "clinical_study": {
        "@rank": "143097", 
        "arm_group": [
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients taking placebo"
            }, 
            {
                "arm_group_label": "Colchicine", 
                "arm_group_type": "Experimental", 
                "description": "Active treatment group"
            }
        ], 
        "brief_summary": {
            "textblock": "There is evidence that inflammatory processes may play a key role during surgical myocardial\n      reperfusion. The hypothesis of this study is that colchicine, an anti-inflammatory agent,\n      may lead to reduction in periprocedural infarct size, when administered during elective\n      coronary artery bypass graft surgery."
        }, 
        "brief_title": "Colchicine in Coronary Artery Bypass Graft (CABG)", 
        "condition": "Elective Coronary Artery Bypass Graft Surgery", 
        "condition_browse": {
            "mesh_term": "Reperfusion Injury"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The study will enroll patients 18 years old or older who are eligible to undergo CABG\n             surgery.\n\n        Exclusion Criteria:\n\n        Excluded are patients:\n\n          -  with age > 80 years old\n\n          -  scheduled for concomitant valve surgery\n\n          -  scheduled for coronary surgery without cardiopulmonary bypass\n\n          -  with peripheral vascular disease a\ufb00ecting the upper limbs\n\n          -  with acute coronary syndrome within the previous 4 weeks\n\n          -  on inotropic or mechanical circulatory support before induction of anaesthesia\n\n          -  with any disorder that could potentially increase preoperative cTnI concentrations\n             (eg, percutaneous coronary intervention within the previous 6 weeks)\n\n          -  with active inflammatory diseases, infectious diseases or known malignancy\n\n          -  under treatment with corticosteroids, anti-inflammatory agents or disease modifying\n             agents\n\n          -  with known hypersensitivity-allergy to colchicine\n\n          -  under chronic treatment with colchicine\n\n          -  with severe renal failure (eGFR < 35 ml/min/1.73 m2)\n\n          -  with hepatic failure (Child - Pugh class B or C)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02122484", 
            "org_study_id": "COL.CABG"
        }, 
        "intervention": {
            "arm_group_label": "Colchicine", 
            "description": "colchicine p.os 0.5 mg bid for two days before undergoing elective CABG surgery and eight days after the operation", 
            "intervention_name": "Colchicine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Colchicine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "reperfusion damage", 
        "lastchanged_date": "April 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Athens", 
                    "country": "Greece", 
                    "state": "Attika", 
                    "zip": "11527"
                }, 
                "name": "Athens General Hospital \"G. Gennimatas\""
            }, 
            "investigator": [
                {
                    "last_name": "Spyridon Deftereos, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Georgios Giannopoulos", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Christos Angelidis, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Greece"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study of Anti-inflammatory Treatment With Colchicine in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery to Reduce Reperfusion Damage", 
        "overall_contact": {
            "email": "spdeftereos@gmail.com", 
            "last_name": "Spyridon Deftereos, MD", 
            "phone": "+302107768560"
        }, 
        "overall_official": {
            "affiliation": "Athens General Hospital \"G. Gennimatas\"", 
            "last_name": "Spyridon Deftereos, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Greece: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Myocardial damage marker levels", 
            "safety_issue": "No", 
            "time_frame": "Days 1-2 post-CABG"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02122484"
        }, 
        "responsible_party": {
            "investigator_affiliation": "G.Gennimatas General Hospital", 
            "investigator_full_name": "Spyridon Deftereos", 
            "investigator_title": "Director, Cardiac Catheterization Department", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "All cause mortality", 
            "safety_issue": "No", 
            "time_frame": "At one and at six months after CABG"
        }, 
        "source": "G.Gennimatas General Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Evangelismos Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "G.Gennimatas General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}